ABIVAX Société Anonyme (NASDAQ:ABVX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

ABIVAX Société Anonyme (NASDAQ:ABVX) has received a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $36.50.

Separately, Laidlaw assumed coverage on ABIVAX Société Anonyme in a research note on Monday, July 29th. They issued a “buy” rating and a $48.00 price objective on the stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets bought a new position in shares of ABIVAX Société Anonyme during the 1st quarter worth approximately $81,000. Capstone Investment Advisors LLC grew its position in ABIVAX Société Anonyme by 9.0% during the 1st quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock worth $900,000 after acquiring an additional 5,199 shares during the last quarter. Kennedy Capital Management LLC grew its position in ABIVAX Société Anonyme by 35.3% during the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after acquiring an additional 31,331 shares during the last quarter. Finally, Janus Henderson Group PLC grew its position in shares of ABIVAX Société Anonyme by 18.2% in the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock valued at $12,113,000 after buying an additional 131,414 shares during the last quarter. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Stock Performance

Shares of NASDAQ ABVX opened at $10.13 on Thursday. ABIVAX Société Anonyme has a one year low of $7.99 and a one year high of $17.02. The business has a 50-day moving average price of $11.18 and a two-hundred day moving average price of $12.85.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.